
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
1 Leukemia Research Fund Centre for Cell and Molecular Biology, Institute of Cancer Research, London, United Kingdom; 2 Childhood Leukaemia Investigation Prague (CLIP), Department of Paediatric Haematology and Oncology, 2nd Medical School, Charles University, Prague, Czech Republic; 3 Childrens Cancer Research Institute and St Anna Kinderspital, Vienna, Austria; 4 Cancer Research UK Childrens Cancer Group, Royal London Hospital, London, United Kingdom; and 5 Charite, Department of Paediatric Oncology/Haematology, Humboldt-University, Campus Virchow-Klinikum, Berlin, Germany
ABSTRACT
Purpose: TEL (ETV6)-AML1 (RUNX1) chimeric gene fusions are frequent genetic abnormalities in childhood acute lymphoblastic leukemia (ALL). They often arise prenatally as early events or initiating events and are complemented by secondary postnatal genetic events of which deletion of the non-rearranged, second TEL allele is the most common. This consistent sequence of molecular pathogenesis facilitates an analysis of the clonal origins of relapse in this leukemia, which has some unusual clinical features.
Experimental Design: We compared the boundaries, by microsatellite mapping, of TEL deletions at relapse versus diagnosis in 15 informative patients. Moreover, we compared the relatedness of diagnostic and relapse clones using immunoglobulin and T-cell receptor genes rearrangements and clonotypic TEL-AML1 genomic fusion.
Results: Five patients retained the apparent same size TEL deletion, seven had larger deletions, and three had smaller deletions at relapse. In all of the cases evaluated, the clonal relatedness of diagnostic and relapse cells was confirmed by the retention of clonotypic TEL-AML1 genomic sequence and/or at least one identical immunoreceptor gene rearrangement.
Conclusions: These data provide further evidence that TEL deletions are secondary to TEL-AML1 fusions in ALL. They are compatible with the novel idea that in at least some cases of childhood ALL, remission occurs with persistence of a preleukemic "fetal" clone, and subsequent relapse reflects the emergence of a new subclone from this reservoir after an independent "second hit," i.e., independent TEL deletion. To our knowledge, the study is the most extensive and comprehensive analysis of the relationship between diagnostic and relapse clones in childhood ALL presented thus far.
This article has been cited by other articles:
![]() |
J. L. Wiemels, J. Hofmann, M. Kang, R. Selzer, R. Green, M. Zhou, S. Zhong, L. Zhang, M. T. Smith, C. Marsit, et al. Chromosome 12p Deletions in TEL-AML1 Childhood Acute Lymphoblastic Leukemia Are Associated with Retrotransposon Elements and Occur Postnatally Cancer Res., December 1, 2008; 68(23): 9935 - 9944. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. G. Mullighan, L. A. Phillips, X. Su, J. Ma, C. B. Miller, S. A. Shurtleff, and J. R. Downing Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia Science, November 28, 2008; 322(5906): 1377 - 1380. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hong, R. Gupta, P. Ancliff, A. Atzberger, J. Brown, S. Soneji, J. Green, S. Colman, W. Piacibello, V. Buckle, et al. Initiating and Cancer-Propagating Cells in TEL-AML1-Associated Childhood Leukemia Science, January 18, 2008; 319(5861): 336 - 339. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. Lacayo, J. F. DiMartino, M. C. Wei, and G. V. Dahl CpG Island Methylator Phenotype and Childhood Leukemia. Clin. Cancer Res., August 15, 2006; 12(16): 4787 - 4789. [Full Text] [PDF] |
||||
![]() |
D. Bhojwani, H. Kang, N. P. Moskowitz, D.-J. Min, H. Lee, J. W. Potter, G. Davidson, C. L. Willman, M. J. Borowitz, I. Belitskaya-Levy, et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study Blood, July 15, 2006; 108(2): 711 - 717. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Loh, M. A. Goldwasser, L. B. Silverman, W.-M. Poon, S. Vattikuti, A. Cardoso, D. S. Neuberg, K. M. Shannon, S. E. Sallan, and D. G. Gilliland Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01 Blood, June 1, 2006; 107(11): 4508 - 4513. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Panzer-Grumayer, G. Cazzaniga, V. H.J. van der Velden, L. del Giudice, M. Peham, G. Mann, C. Eckert, A. Schrauder, G. Germano, J. Harbott, et al. Immunogenotype Changes Prevail in Relapses of Young Children with TEL-AML1-Positive Acute Lymphoblastic Leukemia and Derive Mainly from Clonal Selection Clin. Cancer Res., November 1, 2005; 11(21): 7720 - 7727. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |